Cortigent

Cortigent operates in the highly specialized cortical neurostimulation and brain-computer-interface segment, where its principal differentiation is the combination of an implantable visual prosthesis, wireless stimulation electronics, software, artificial intelligence, and clinical experience inherited from Second Sight Medical Products. Its Orion system targets the visual cortex directly, potentially bypassing damaged portions of the eye or optic pathway. This positions Cortigent alongside companies such as Neuralink, Synchron, Blackrock Neurotech, and Paradromics, although the product strategies differ materially. Neuralink and Paradromics emphasize high-bandwidth brain-computer interfaces, while Synchron focuses on minimally invasive vascular access and Blackrock Neurotech has pursued implanted interfaces for communication and control. Cortigent’s focus is narrower and therapeutically specific: restoring elements of vision and motor function rather than providing a general-purpose interface. The company also has historical experience with Argus II, an implantable retinal stimulation device that delivered visual perception but is now discontinued. Cortigent’s market position remains developmental because Orion and its stroke-recovery system are investigational, public financing and revenue details are unavailable, and no regulatory commercialization milestone is identified. The 2026 ClearOne merger may provide a new route to capital-market support, but its long-term effect on product development remains uncertain.

Cortigent’s trajectory reflects a shift from legacy retinal prosthetics toward targeted cortical stimulation. The company was formed in 2023 to continue the business of Second Sight Medical Products, bringing forward experience associated with Argus II while developing Orion, a 60-electrode visual-cortex implant. The key technical inflection point is the move from stimulating the retina to stimulating the visual cortex, expanding the potential addressable population to people whose blindness involves damaged or absent visual pathways. In 2026, the company presented Orion-related work at NANS and reported six-year system results, providing evidence of continued clinical follow-up and device longevity. A second development path applies targeted neurostimulation to arm and hand recovery for people partially paralyzed by stroke, broadening the platform beyond artificial vision. The Jul 2, 2026 stock-based merger with ClearOne is the clearest corporate inflection point and may alter Cortigent’s access to resources, governance, and commercialization capabilities. Growth therefore appears driven primarily by technology maturation, clinical evidence, and corporate restructuring rather than demonstrated commercial scale.